GLOBAL
Our Priority is to Put You at the Center
At Alnylam, we want to understand your journey, your experiences, and your unique needs. You inspire us to learn as much as we can, to persevere and continue to advance the development of potential therapies to treat rare and serious diseases. We take pride in working together to achieve mutual goals such as increasing awareness, enabling diagnosis, and providing education and services to support patient communities. We have a dedicated team to ensure your perspectives are represented at Alnylam. If you are an advocate interested in helping us increase awareness of rare diseases, please send an email to PatientAdvocacy@alnylam.com
Understanding RNAi
RNA interference (RNAi) is the core discovery that forms the therapies Alnylam is developing. It is recognized as a major scientific breakthrough—but how does it work, exactly?
From Possibility to Patients: Understanding RNAi
Learn about RNAi and our investigational therapies
Alnylam is focused on 4 Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS) and ocular diseases
Alnylam is dedicated to providing support for affected individuals, families, and caregivers
OUR
FOCUS ON YOU
A Family Living with
Primary Hyperoxaluria Type 1 (PH1)
Get more information about primary hyperoxaluria.
CLINICAL TRIALS
Interested in learning about our hATTR amyloidosis studies? Get started here.
ALNYLAM ASSIST
Alnylam AssistTM helps patients access ONPATTRO® (patisiran) with personalized support.
Visit Site >
ALNYLAM ACT
Alnylam Act provides no-charge, independent genetic testing and counseling to individuals in the US and Canada who may have hATTR amyloidosis, acute hepatic porphyria, or primary hyperoxaluria type 1 (PH1).
APPROVED IN THE U.S.
Learn more about an FDA-approved treatment option available for patients in the U.S.
Learn More >